[he importance of mTOR hyperactivity and RICTOR amplification, and the associated targeted therapy possibilities in...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer treatment failures and drug resistance are often linked to aberrant signaling networks, notably PI3K/Akt/mTOR hyperactivity driven by oncogenic mutations.
• Mechanistic target of rapamycin (mTOR) dysregulation, identified decades ago, is a hallmark of numerous tumors, impacting therapeutic efficacy.

Purpose of the Study:

• To review the significance of mTOR dysregulation in cancer.
• To delineate the distinct activities, functions, and testability of mTOR kinase complexes (mTORC1 and mTORC2).
• To discuss the implications of genetic alterations, such as RICTOR amplification, for targeted therapy development.

Main Methods:

• Literature review summarizing current knowledge on mTOR pathway dysregulation in cancer.
• Comparative analysis of mTORC1 and mTORC2 complexes regarding structure, regulation, and inhibitor sensitivity.
• Discussion of genetic alterations and their role in mTOR hyperactivity and targeted therapy.

Main Results:

• mTORC1 and mTORC2 complexes exhibit distinct structures, regulatory mechanisms, and sensitivities to inhibitors.
• Genetic alterations, including RICTOR amplification, contribute to mTOR hyperactivity and are crucial for targeted therapy development.
• First-generation mTOR inhibitors like rapamycin may be ineffective against mTORC2 hyperactivity.

Conclusions:

• Assessing a patient's mTOR activity profile is recommended before initiating mTOR inhibitor therapy.
• New inhibitors and combination therapies show promise for advanced-stage cancer patients selected by molecular markers.
• Targeting specific mTOR complexes offers a promising avenue for overcoming therapeutic resistance in cancer.